Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife’s Chinese provinces

This article was originally published in The Tan Sheet

Executive Summary

China's Ministry of Commerce grants the Los Angeles-based nutritional products direct-seller five additional licenses to conduct direct-selling business in the Beijing, Guangdong, Shandong, Zhejiang and Guizhou provinces. The licenses are effective immediately except for the Beijing province, which will activate after the firm opens service outlets, Herbalife says July 20. Herbalife received its first direct-selling license for China in March 2007, covering Suzhou and Nanjing in the Jiangsu province. The licenses allow distributors to conduct business outside retail locations in the specific province and cities ("The Tan Sheet" April 2, 2007, In Brief)...

You may also be interested in...

Social Clubs Help Deepen Herbalife’s Reach In Existing Markets

Herbalife is focusing more on extending the "daily consumptive model" for direct-selling nutritional products, which has driven the firm's double-digit sales growth for 18 consecutive quarters, deeper into its existing markets than on reaching additional markets

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts